Corinne Jenkins
Stock Analyst at Goldman Sachs
(2.45)
# 3,206
Out of 5,182 analysts
59
Total ratings
45.65%
Success rate
2.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Maintains: Neutral | $31 → $35 | $29.48 | +18.72% | 7 | Apr 14, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $24 → $33 | $27.85 | +18.49% | 7 | Dec 15, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $141 → $157 | $85.20 | +84.27% | 11 | Dec 12, 2025 | |
| GERN Geron | Reinstates: Sell | $1 | $1.53 | -34.64% | 4 | Jul 10, 2025 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $35.38 | -37.82% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $7.72 | +94.30% | 2 | May 14, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $2.80 | +364.29% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $31.05 | -9.82% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $1.09 | +5,771.56% | 6 | Aug 15, 2023 | |
| ACRS Aclaris Therapeutics | Maintains: Buy | $25 → $21 | $4.41 | +376.19% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $52.95 | -73.56% | 2 | Dec 20, 2022 |
IDEAYA Biosciences
Apr 14, 2026
Maintains: Neutral
Price Target: $31 → $35
Current: $29.48
Upside: +18.72%
Roivant Sciences
Dec 15, 2025
Maintains: Buy
Price Target: $24 → $33
Current: $27.85
Upside: +18.49%
Rhythm Pharmaceuticals
Dec 12, 2025
Maintains: Buy
Price Target: $141 → $157
Current: $85.20
Upside: +84.27%
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.53
Upside: -34.64%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $35.38
Upside: -37.82%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $7.72
Upside: +94.30%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $2.80
Upside: +364.29%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $31.05
Upside: -9.82%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $1.09
Upside: +5,771.56%
Aclaris Therapeutics
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $4.41
Upside: +376.19%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $52.95
Upside: -73.56%